145 related articles for article (PubMed ID: 38445044)
1. A positive take on negative selection for CAR-T manufacturing.
Orentas RJ
Mol Ther Methods Clin Dev; 2024 Mar; 32(1):101218. PubMed ID: 38445044
[No Abstract] [Full Text] [Related]
2. Toward Rapid, Widely Available Autologous CAR-T Cell Therapy - Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital.
Hort S; Herbst L; Bäckel N; Erkens F; Niessing B; Frye M; König N; Papantoniou I; Hudecek M; Jacobs JJL; Schmitt RH
Front Med (Lausanne); 2022; 9():913287. PubMed ID: 35733863
[TBL] [Abstract][Full Text] [Related]
3. Manufacture of CD22 CAR T cells following positive versus negative selection results in distinct cytokine secretion profiles and γδ T cell output.
Song HW; Benzaoui M; Dwivedi A; Underwood S; Shao L; Achar S; Posarac V; Remley VA; Prochazkova M; Cai Y; Jin P; Somerville RP; Stroncek DF; Altan-Bonnet G; Shah NN; Chien CD; Taylor N; Highfill SL
Mol Ther Methods Clin Dev; 2024 Mar; 32(1):101171. PubMed ID: 38298420
[TBL] [Abstract][Full Text] [Related]
4. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
Teoh J; Brown LF
Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
[TBL] [Abstract][Full Text] [Related]
5. Targeted multi-epitope switching enables straightforward positive/negative selection of CAR T cells.
Mosti L; Langner LM; Chmielewski KO; Arbuthnot P; Alzubi J; Cathomen T
Gene Ther; 2021 Sep; 28(9):602-612. PubMed ID: 33526841
[TBL] [Abstract][Full Text] [Related]
6. Scalable Manufacturing of CAR T cells for Cancer Immunotherapy.
Abou-El-Enein M; Elsallab M; Feldman SA; Fesnak AD; Heslop HE; Marks P; Till BG; Bauer G; Savoldo B
Blood Cancer Discov; 2021 Sep; 2(5):408-422. PubMed ID: 34568831
[TBL] [Abstract][Full Text] [Related]
7. Manufacturing NKG2D CAR-T cells with piggyBac transposon vectors and K562 artificial antigen-presenting cells.
Tay JCK; Wang J; Du Z; Ng YY; Li Z; Ren Y; Zhang C; Zhu J; Xu XH; Wang S
Mol Ther Methods Clin Dev; 2021 Jun; 21():107-120. PubMed ID: 33816644
[TBL] [Abstract][Full Text] [Related]
8. Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene.
Casucci M; Falcone L; Camisa B; Norelli M; Porcellini S; Stornaiuolo A; Ciceri F; Traversari C; Bordignon C; Bonini C; Bondanza A
Front Immunol; 2018; 9():507. PubMed ID: 29619024
[TBL] [Abstract][Full Text] [Related]
9. Functionality and Cell Senescence of CD4/ CD8-Selected CD20 CAR T Cells Manufactured Using the Automated CliniMACS Prodigy® Platform.
Aleksandrova K; Leise J; Priesner C; Melk A; Kubaink F; Abken H; Hombach A; Aktas M; Essl M; Bürger I; Kaiser A; Rauser G; Jurk M; Goudeva L; Glienke W; Arseniev L; Esser R; Köhl U
Transfus Med Hemother; 2019 Feb; 46(1):47-54. PubMed ID: 31244581
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor.
Machietto R; Giacobbe N; Perazzelli J; Hofmann TJ; Barz Leahy A; Grupp SA; Wang Y; Kadauke S
J Vis Exp; 2023 Aug; (198):. PubMed ID: 37607096
[TBL] [Abstract][Full Text] [Related]
11. Next-Generation Manufacturing Protocols Enriching T
Arcangeli S; Falcone L; Camisa B; De Girardi F; Biondi M; Giglio F; Ciceri F; Bonini C; Bondanza A; Casucci M
Front Immunol; 2020; 11():1217. PubMed ID: 32636841
[TBL] [Abstract][Full Text] [Related]
12. The inhibitory receptors PD1, Tim3, and A2aR are highly expressed during mesoCAR T cell manufacturing in advanced human epithelial ovarian cancer.
Akbari B; Soltantoyeh T; Shahosseini Z; Yarandi F; Hadjati J; Mirzaei HR
Cancer Cell Int; 2023 May; 23(1):104. PubMed ID: 37244991
[TBL] [Abstract][Full Text] [Related]
13. Strategies for manufacturing cell therapy products aligned with patient needs.
Guha P; Katz SC
Methods Cell Biol; 2022; 167():203-226. PubMed ID: 35152997
[TBL] [Abstract][Full Text] [Related]
14. Development of a microfluidic cell transfection device into gene-edited CAR T cell manufacturing workflow.
Yu T; Jhita N; Shankles P; Fedanov A; Kramer N; Raikar SS; Sulchek T
Lab Chip; 2023 Nov; 23(22):4804-4820. PubMed ID: 37830228
[TBL] [Abstract][Full Text] [Related]
15. Automated generation of gene-edited CAR T cells at clinical scale.
Alzubi J; Lock D; Rhiel M; Schmitz S; Wild S; Mussolino C; Hildenbeutel M; Brandes C; Rositzka J; Lennartz S; Haas SA; Chmielewski KO; Schaser T; Kaiser A; Cathomen T; Cornu TI
Mol Ther Methods Clin Dev; 2021 Mar; 20():379-388. PubMed ID: 33575430
[TBL] [Abstract][Full Text] [Related]
16. Chimeric Antigen Receptor Structure and Manufacturing of Clinical Grade CAR Engineered Cells using Different Bioreactors.
Syed F; El Fakih R; Alahmari AD; Osman Ali AS; Aljurf M
Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):137-152. PubMed ID: 36395497
[TBL] [Abstract][Full Text] [Related]
17. TCR-independent Activation in Presence of a Src-family Kinase Inhibitor Improves CAR-T Cell Product Attributes.
Lamture G; Baer A; Fischer JW; Colon-Moran W; Bhattarai N
J Immunother; 2022 Apr; 45(3):139-149. PubMed ID: 34802014
[TBL] [Abstract][Full Text] [Related]
18. Enzymatically produced piggyBac transposon vectors for efficient non-viral manufacturing of CD19-specific CAR T cells.
Kaštánková I; Štach M; Žižková H; Ptáčková P; Šmilauerová K; Mucha M; Šroller V; Otáhal P
Mol Ther Methods Clin Dev; 2021 Dec; 23():119-127. PubMed ID: 34631931
[TBL] [Abstract][Full Text] [Related]
19. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.
Shah NN; Highfill SL; Shalabi H; Yates B; Jin J; Wolters PL; Ombrello A; Steinberg SM; Martin S; Delbrook C; Hoffman L; Little L; Ponduri A; Qin H; Qureshi H; Dulau-Florea A; Salem D; Wang HW; Yuan C; Stetler-Stevenson M; Panch S; Tran M; Mackall CL; Stroncek DF; Fry TJ
J Clin Oncol; 2020 Jun; 38(17):1938-1950. PubMed ID: 32286905
[TBL] [Abstract][Full Text] [Related]
20. Toward an Optimized Process for Clinical Manufacturing of CAR-Treg Cell Therapy.
Fritsche E; Volk HD; Reinke P; Abou-El-Enein M
Trends Biotechnol; 2020 Oct; 38(10):1099-1112. PubMed ID: 31982150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
